Analysis of R&D efficiency of new biopharmaceuticals based on large-scale quantitative analysis and careful case analysis

Abstract

Research on the R&D efficiency of new biopharmaceuticals is geared towards enhancing efficiencies, such as improving drug development technologies and therefore speeding up the discovery and development of new treatments. Organisation theory is one way of exploring R&D efficiency and involves studying the behaviour of organisations with a view to enhancing organisational efficiency. Professor Tetsuya Miyashige and his team at the National Institute of Technology, Toyama College, Japan, are using large-scale quantitative analysis and careful case analysis to analyse the R&D efficiency of new pharmaceuticals. The goal is to contribute to the R&D management of pharmaceutical companies and to industrial economic policy for the pharmaceutical industry. A particular focus for the researcher is using biotechnology to analyse the R&D efficiency of 'antibody drug = biomedicine' in pharmaceutical companies. In collaboration with econometrician Professor Atsushi Fujii, University of Kitakyushu, Miyashige worked on the separation of R&D processes in biopharmaceutical R&D. This work involved analysing the R&D productivity of a biopharmaceutical company, with a focus on separation of the R&D processes and looking at blockbusters and biotech drugs. Another line of work involved empirically analysing the differences between blockbuster production in Japanese firms and in US/EU firms.